| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 1g |
|
| Targets |
Methyl (R)-2-(1-((2-amino-5-bromopyridin-3-yl)oxy)ethyl)-4-fluorobenzoate does not have a specific biological target. It is a synthetic intermediate used to prepare other compounds. The compound's structure suggests it may be used in the synthesis of pharmaceutical agents.
|
|---|---|
| ln Vitro |
In vitro, Methyl (R)-2-(1-((2-amino-5-bromopyridin-3-yl)oxy)ethyl)-4-fluorobenzoate is used as a research chemical. Its activity is chemical rather than biological. The compound is a building block for the preparation of various compounds.
|
| ln Vivo |
In vivo, Methyl (R)-2-(1-((2-amino-5-bromopyridin-3-yl)oxy)ethyl)-4-fluorobenzoate is not administered as a therapeutic agent. Its importance lies in its role as a building block for the synthesis of active pharmaceutical ingredients.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable to Methyl (R)-2-(1-((2-amino-5-bromopyridin-3-yl)oxy)ethyl)-4-fluorobenzoate, as it is a synthetic intermediate. Its characterization involves chemical analysis to confirm its structure and purity.
|
| Cell Assay |
In vitro cellular assays are not applicable to Methyl (R)-2-(1-((2-amino-5-bromopyridin-3-yl)oxy)ethyl)-4-fluorobenzoate, as it is not used directly in cell-based studies. The compound is used in chemical synthesis to produce other compounds.
|
| Animal Protocol |
In vivo animal studies are not applicable to Methyl (R)-2-(1-((2-amino-5-bromopyridin-3-yl)oxy)ethyl)-4-fluorobenzoate, as it is not a drug candidate. The compound is used in the synthesis of other compounds.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Methyl (R)-2-(1-((2-amino-5-bromopyridin-3-yl)oxy)ethyl)-4-fluorobenzoate are not relevant, as the compound is not administered as a drug. Its properties as a chemical intermediate are characterized for synthetic purposes.
|
| Toxicity/Toxicokinetics |
Methyl (R)-2-(1-((2-amino-5-bromopyridin-3-yl)oxy)ethyl)-4-fluorobenzoate is a chemical intermediate and not a drug; therefore, toxicological data are not typically reported. The compound is intended for research use only. Standard safety precautions should be taken when handling the compound.
|
| Additional Infomation |
Methyl (R)-2-(1-((2-amino-5-bromopyridin-3-yl)oxy)ethyl)-4-fluorobenzoate is a research chemical used as a building block in organic synthesis. It is a pyridine-containing compound and is not approved for clinical use.
|
| Exact Mass |
368.017
|
|---|---|
| CAS # |
1454848-00-0
|
| PubChem CID |
89808256
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
452.5±45.0 °C at 760 mmHg
|
| Flash Point |
227.5±28.7 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.600
|
| LogP |
4.76
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
22
|
| Complexity |
388
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C[C@H](C1=C(C=CC(=C1)F)C(=O)OC)OC2=C(N=CC(=C2)Br)N
|
| InChi Key |
NEXBDDSPNVIGGI-MRVPVSSYSA-N
|
| InChi Code |
InChI=1S/C15H14BrFN2O3/c1-8(22-13-5-9(16)7-19-14(13)18)12-6-10(17)3-4-11(12)15(20)21-2/h3-8H,1-2H3,(H2,18,19)/t8-/m1/s1
|
| Chemical Name |
methyl 2-[(1R)-1-(2-amino-5-bromopyridin-3-yl)oxyethyl]-4-fluorobenzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
